FN-1501 was tested in patients with advanced solid tumors using a tyrosine kinase inhibitor with significant potency against FLT3, a target that led to the development of agents that have profoundly advanced the standard of care for FLT3-mutated AML (e.g., midostaurin, gilteritinib). This evidence concerns the gene FLT3 and acute myeloid leukemia.